Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.47 |
| ▸ | MAPT | P10636 | 8/20 | 0.47 |
| ▸ | MEN1 | O00255 | 6/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 4/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | MGLL | Q99685 | 1/20 | 0.41 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18133119 | 0.85 | ALDH1A1 (0.57) | ALDH1A1MAPTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL4404651 | 0.77 | KMT2A (0.52) | ALDH1A1MAPTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL31648930 | 0.77 | ALDH1A1 (0.52) | ALDH1A1MAPTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL12355604 | 0.76 | ALDH1A1 (0.36) | ALDH1A1MAPTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL15561636 | 0.76 | ALDH1A1 (0.46) | ALDH1A1MAPTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL23118466 | 0.75 | ALDH1A1 (0.43) | ALDH1A1MAPTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL18692397 | 0.74 | MAPT (0.49) | ALDH1A1MAPTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL24916802 | 0.74 | MAPT (0.52) | ALDH1A1MAPTMEN1KMT2ASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL23088234 | 0.74 | ALDH1A1 (0.42) | ALDH1A1MAPTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL4411526 | 0.72 | ALDH1A1 (0.45) | ALDH1A1MAPTMEN1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4747260-A1 | MACROCYCLES FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. Hoffmann-La Roche AG (CH) | 2026-05-27 | — | — | EP | disclosed |
| EP-4739670-A1 | MACROCYCLES FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. Hoffmann-La Roche AG (CH) | 2026-05-13 | — | — | EP | disclosed |
| US-20260070927-A1 | INDAZOLE MACROCYCLES FOR THE TREATMENT OF AUTOIMMUNE DISEASE | HOFFMANN-LA ROCHE INC. (US) | 2026-03-12 | — | — | US | disclosed |
| EP-4536662-A1 | INDAZOLE MACROCYCLES FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. Hoffmann-La Roche AG (CH) | 2025-04-16 | — | — | EP | disclosed |
| WO-2025021666-A1 | MACROCYCLES FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2025-01-30 | — | — | WO | disclosed |
| WO-2025012057-A1 | MACROCYCLES FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2025-01-16 | — | — | WO | disclosed |
| EP-4472739-A1 | IMIDAZOLE MACROCYCLES FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. Hoffmann-La Roche AG (CH) | 2024-12-11 | — | — | EP | disclosed |
| WO-2023237457-A1 | INDAZOLE MACROCYCLES FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2023-12-14 | — | — | WO | disclosed |
| WO-2023237457-A1 | INDAZOLE MACROCYCLES FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2023-12-14 | — | — | WO | disclosed |
| WO-2023148129-A1 | IMIDAZOLE MACROCYCLES FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2023-08-10 | — | — | WO | disclosed |
| EP-2170879-B1 | 1-CYANOCYCLOPROPYL-DERIVATIVES AS CATHEPSIN K INHIBITORS | ASTRAZENECA AB (SE) | 2013-01-16 | — | — | EP | disclosed |
| EP-2170879-B1 | 1-CYANOCYCLOPROPYL-DERIVATIVES AS CATHEPSIN K INHIBITORS | ASTRAZENECA AB (SE) | 2013-01-16 | — | — | EP | disclosed |
| US-8008279-B2 | Compound—827 | ASTRAZENECA AB (SE) | 2011-08-30 | — | — | US | disclosed |
| EP-2170879-A1 | 1-CYANOCYCLOPROPYL-DERIVATIVES AS CATHEPSIN K INHIBITORS | AstraZeneca AB (SE) | 2010-04-07 | — | — | EP | disclosed |
| WO-2009001129-A9 | 1-CYANOCYCLOPROPYL-DERIVATIVES AS CATHEPSIN K INHIBITORS | ASTRAZENECA AB (SE) | 2010-02-04 | — | — | WO | disclosed |
| WO-2009001129-A9 | 1-CYANOCYCLOPROPYL-DERIVATIVES AS CATHEPSIN K INHIBITORS | ASTRAZENECA AB (SE) | 2010-02-04 | — | — | WO | disclosed |
| US-20090012077-A1 | Novel Compound - 827 | ASTRAZENECA AB (SE) | 2009-01-08 | — | — | US | disclosed |
| WO-2009001129-A1 | 1-CYANOCYCLOPROPYL-DERIVATIVES AS CATHEPSIN K INHIBITORS | ASTRAZENECA AB (SE) | 2008-12-31 | — | — | WO | disclosed |
| WO-2009001129-A1 | 1-CYANOCYCLOPROPYL-DERIVATIVES AS CATHEPSIN K INHIBITORS | ASTRAZENECA AB (SE) | 2008-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260070927-A1 | INDAZOLE MACROCYCLES FOR THE TREATMENT OF AUTOIMMUNE DISEASE | MALT1, CCR1, CCR6 | ALDH1A1 335/4885MAPT 4693/4885MEN1 155/4885 |
| US-20090012077-A1 | Novel Compound - 827 | CTSS, CTSF, CTSB | ALDH1A1 3966/4885MAPT 2312/4885MEN1 3351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.